Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia

American Journal of Otolaryngology - Head and Neck Medicine and Surgery

Volumn 33, Issue 3, 2012, Pages 349-351

  Brinkerhoff, Brian T ^a   Choong, Nicholas W ^a   Treisman, Jonathan S ^b   Poetker, David M ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Wheaton Franciscan Cancer Care Reiman Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; HEMOGLOBIN; NOSE SPRAY;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; CAUTERIZATION; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC DISEASE; EPISTAXIS; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAINTENANCE THERAPY; NEBULIZER; NEODYMIUM LASER; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRANASAL; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; PLATELET COUNT; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84860378849     PISSN: 01960709     EISSN: 1532818X     Source Type: Journal    
DOI: 10.1016/j.amjoto.2011.07.012     Document Type: Article

References (11)

1. C.L. Shovlin, A.E. Guttmacher, and E. Buscarini Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome) Am J Med Genet 91 2000 66 67
2. H. Sadick, F. Riedel, and R. Naim Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression Haematologica 90 2005 818 828
3. D. Flieger, S. Hainke, and W. Fischbach Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab Ann Hematol 85 2006 631 632
4. P. Bose, J.L. Holter, and G.B. Selby Bevacizumab in hereditary hemorrhagic telangiectasia N Engl J Med 360 2009 2143 2144
5. B. Brinkerhoff, D. Poetker, and N. Choong Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia N Engl J Med 364 2011 688 689
6. S. Chen, T. Karnezis, and T. Davidson Safety of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia- associated epistaxis Laryngoscope 121 2011 644 646
7. E. Galfrascoli Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis Dig Liver Dis 43 2011 286 294
8. E. Senkus Cardiovascular effects of systemic cancer treatment Cancer Treat Rev 2010
9. T.M. Davidson, S.E. Olitsky, and J.L. Wei Hereditary hemorrhagic telangiectasia/Avastin Laryngoscope 120 2010 432
10. J. Simonds, F. Miller, and J. Mandel The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia Laryngoscope 119 2009 988 992
11. J.B. Hoag, and P. Terry An epistaxis severity score for hereditary hemorrhagic telangiectasia Laryngoscope 120 2010 838 843